INCY
IncyteBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-22
Current thesis
The post-earnings bull read is that Incyte delivered a clean quarter, kept 2026 guidance intact, showed broad commercial growth beyond Jakafi, and paired that with multiple dated regulatory and pipeline milestones. The median analyst target in the packet, $108.8095, implies moderate upside from the $97.74 anchor.
Posture
Constructive
Lead driver
Value
What changed
Next scheduled catalyst: earnings 2026-07-28 · BMO.
What can break
Full-year 2026 guidance was reaffirmed rather than raised, leaving less room for execution slips if the commercial mix softens.
Momentum
63
Value
66
Sentiment
40
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $109.00 · Bull $120.00 · Bear $86.00
Earnings
2026-07-28 · BMO
Data freshness
Prices
As of 2026-07-22
Fundamentals
As of 2026-07-21 • Vendor: Data Vendor v1
Scores
As of 2026-07-22 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-29 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-22
Investment thesis
As of 2026-07-22
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $116.38
Why
Momentum63 · Δ7d +31.6
Value66 · Δ7d -0.3
Sentiment40 · Δ7d -2.5
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Value · See fundamentals
Momentum
63
26% active weight
Current posture
7d trendImproving
Δ7d
+31.6
Δ21d
+11.8
Value
66
39% active weight
Current posture
7d trendFlat
Δ7d
-0.3
Δ21d
-0.4
Sentiment
40
34% active weight
Current posture
7d trendSoftening
Δ7d
-2.5
Δ21d
-5.0
Why this grade
Composite grade B. Momentum 63.3 / Value 65.8 / Sentiment 40.2
Fundamentals (TTM)As of 2026-07-21
Fundamentals (TTM)
As of 2026-07-21
Market Cap
$23.45B
Beta
0.83
Shares Out
199.78M
P/E (TTM)
17.2
P/S (TTM)
4.15
P/FCF (TTM)
16.69
Rev YoY
+20.9%
EPS YoY
+83.7%
Gross Margin
+91.2%
Op Margin
+30.8%
Net Debt
-$3.53B
Current Ratio
3.68
As of 2026-07-22 • Updated nightlySource: Internal modelMethodology